New Molecular Insights into the Pathogenesis and Drug Development of Neurodegenerative Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 574

Special Issue Editors

E-Mail Website
Guest Editor
Faculty of Health Sciences, University of Macau, Taipa, Macau
Interests: neurodegenerative diseases; Alzheimer's disease; amyotrophic lateral sclerosis; ataxia–telangiectasia; pathogenesis; molecular mechanisms; drug screening; pharmacological evaluations; drug repurposing; preclinical study

E-Mail Website
Guest Editor
Department of Pediatrics, University of California, San Francisco, CA, USA
Interests: neurodegenerative diseases; Alzheimer's disease; glial biology; microglial function; neuroinflammation; neuroimmune interactions; G protein-coupled receptor; molecular signaling pathway; therapeutic strategies

Special Issue Information

Dear Colleagues,

The prevalence of neurodegenerative diseases is rapidly increasing with the aging trend of global populations, severely threatening human health and creating a societal burden; existing drugs in the market temporarily relieve symptoms but cannot prevent disease progression. Therefore, the development of more effective drugs for neurodegenerative diseases using efficient strategies has become a pressing need. One of the challenges for drug development is the incomplete understanding of the underlying mechanisms of disease pathogenesis.

This Special Issue aims to collect high-quality papers featuring emerging research areas in neurodegenerative diseases, with a particular emphasis on the cellular and molecular mechanisms of disease pathogenesis. It also highlights novel drug discovery targeting neurodegeneration, drug repurposing, mode of action studies on drug leads, and pharmacological evaluations of different models, such as brain organoids and animals. Overall, we hope that this Special Issue will provide a theoretical and technical basis for further preclinical and clinical studies, as well as promote the translational application of valuable candidates as potential therapeutic agents in treating neurodegenerative diseases.

Dr. Aifang Cheng
Dr. Beika Zhu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neurodegenerative diseases
  • pathogenesis
  • molecular mechanisms
  • high-throughput drug screening
  • drug repurposing
  • cellular and animal models
  • brain organoids
  • mode of action
  • pharmacological evaluations
  • preclinical study

Published Papers

This special issue is now open for submission.
Back to TopTop